EP Patent

EP4321162A1 — Antiviral agents for the treatment of infections by coronaviruses

Assigned to Consejo Superior de Investigaciones Cientificas CSIC · Expires 2024-02-14 · 2y expired

What this patent protects

The invention provides a CFTR modulator compound selected from the group consisting of 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol -5-yl) cyclopropanecarbonyl] amino] -3-methylpyridin -2-yl]benzoic acid and/or N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide and p…

USPTO Abstract

The invention provides a CFTR modulator compound selected from the group consisting of 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol -5-yl) cyclopropanecarbonyl] amino] -3-methylpyridin -2-yl]benzoic acid and/or N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide and pharmaceutically acceptable salts or deuterated derivatives thereof for use in the treatment of an infection produced by a Betacoronavirus in a subject and compositions comprising said compounds.

Drugs covered by this patent

Patent Metadata

Patent number
EP4321162A1
Jurisdiction
EP
Classification
—
Expires
2024-02-14
Drug substance claim
No
Drug product claim
No
Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.